Reply to: "Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration" and "NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002".

Authors

Baoqing Chen, Zimeng Li, Xingyuan Cheng, Mian Xi

Published in

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Pages JCO2601677. Aug 05, 2026. Epub Aug 05, 2026.

PMID:
42555897
Bibliographic data and abstract were imported from PubMed on 06 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.